Cart
sales@molnova.com
JI069
CAS No. 850019-35-1
JI069( —— )
Catalog No. M37038 CAS No. 850019-35-1
JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1773 | Get Quote |
|
| 500MG | 3537 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameJI069
-
NoteResearch use only, not for human use.
-
Brief DescriptionJI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
-
DescriptionJI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT | JAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number850019-35-1
-
Formula Weight387.24
-
Molecular FormulaC15H12Cl2N2O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N)C=1C=CSC1NC(=O)COC(=O)CC=2C(Cl)=CC=CC2Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
-
S3I-M2001
S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.
-
MM-206
A novel small molecule STAT3 inhibitor that inhibits STAT3 DNA binding activity with IC50 of 1.16 uM.
